Johnson & Johnson has announced positive topline results from its Phase 3 MajesTEC-9 trial, reporting that TECVAYLI (teclistamab-cqyv) monotherapy significantly reduced the risk of disease progression or death by 71 percent and the risk of death by 40 percent compared to standard-of-care regimens in patients with relapsed or refractory multiple myeloma previously exposed to anti-CD38 antibodies and lenalidomide.

This is the second major trial to support the use of TECVAYLI-based regimens in earlier lines of therapy, building upon the earlier MajesTEC-3 data which evaluated its use in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj). With a treatment landscape increasingly shaped by bispecific antibody platforms and resistance to standard immunomodulatory therapies, these results represent a strategic inflection point for Johnson & Johnson’s myeloma portfolio.

What this trial result enables in refractory multiple myeloma where options are shrinking

The most consequential shift enabled by MajesTEC-9 is the potential redefinition of treatment sequencing. TECVAYLI was previously positioned as a later-line therapy following at least four prior lines, but this data supports its monotherapy use as early as second-line in patients previously treated with anti-CD38 therapies and lenalidomide. The fact that the enrolled population was overwhelmingly refractory to these two key classes—85 percent to anti-CD38 and 79 percent to lenalidomide—raises the relevance of this study for real-world practice, where rapid cycling through regimens is common.

This directly addresses the growing clinical need for therapies that retain efficacy despite overlapping resistance patterns. Clinicians tracking this space have noted that many newly relapsed patients quickly exhaust CD38- and IMiD-based backbones. With limited sequencing options left, especially in community practice settings, a durable, off-the-shelf T-cell redirecting agent like teclistamab may fill a pressing gap.

The standard-of-care comparators in MajesTEC-9—pomalidomide, bortezomib, and dexamethasone (PVd), or carfilzomib and dexamethasone (Kd)—remain widely used regimens, but both are burdened by cumulative toxicity and immunosuppressive effects. Demonstrating superiority over these regimens in a heavily pretreated, refractory population underscores both the efficacy and relative tolerability of teclistamab.

How the MajesTEC-9 design strengthens regulatory and clinical adoption prospects

What makes MajesTEC-9 more than an incremental update is its prospective design, population selection, and early statistical significance. It was not merely a confirmatory trial but rather a head-to-head, superiority-designed study comparing TECVAYLI to active control arms aligned with current practice. Unlike basket-style or single-arm confirmatory extensions, MajesTEC-9 provides the kind of direct comparative evidence that regulators and payers typically require when considering label expansions into earlier lines of therapy.

Interim results prompted the Independent Data Monitoring Committee to recommend unblinding the study, suggesting robust hazard ratios and sufficient power to meet pre-specified efficacy endpoints. The 71 percent reduction in disease progression or death (HR=0.29) and 40 percent reduction in mortality (HR=0.60) were both statistically and clinically significant, lending strength to future U.S. Food and Drug Administration and European Medicines Agency submissions.

Safety findings were consistent with previously known risks of TECVAYLI. No new adverse signals were detected, and the profile remained manageable using step-up dosing protocols. This will help reinforce confidence among clinicians concerned about cytokine release syndrome (CRS), neurotoxicity, or ICANS, which are the class-defining safety concerns for bispecific T-cell engagers.

What this signals for bispecifics versus CAR-T in earlier multiple myeloma lines

MajesTEC-9 also reopens the competitive debate between bispecific antibodies and autologous CAR-T cell therapies in multiple myeloma. While idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have demonstrated durable responses, their rollout has been hindered by logistical bottlenecks, cell manufacturing delays, and patient eligibility constraints.

By contrast, TECVAYLI’s subcutaneous, off-the-shelf profile offers immediate access with minimal lead time—critical for patients relapsing rapidly or presenting in non-academic centers. The ability to administer it in community oncology settings, with increasingly standardized safety monitoring protocols, has expanded its reach beyond the CAR-T-eligible subset.

Industry analysts suggest that Johnson & Johnson’s long-term strategy may involve positioning TECVAYLI as the default T-cell redirecting option in earlier lines, while reserving CAR-T therapies such as cilta-cel (CARVYKTI) for younger, fit patients who relapse after bispecific exposure. This bifurcation of immunotherapy lines could reshape treatment pathways and reimbursement decisions by payers.

Why this puts pressure on competing regimens from Bristol Myers Squibb and Pfizer

The implications of MajesTEC-9 extend beyond Johnson & Johnson’s portfolio. Bristol Myers Squibb and Pfizer have invested heavily in their own bispecific antibody pipelines, including elranatamab and talquetamab, each with distinct targets (e.g., GPRC5D). However, without a clear edge in PFS or OS over TECVAYLI, these assets may now face greater scrutiny in terms of comparative effectiveness and commercialization readiness.

Moreover, the combination of TECVAYLI with DARZALEX FASPRO, as studied in MajesTEC-3, adds depth to the bispecific platform. Johnson & Johnson has been methodically layering these regimens across the disease continuum, now offering both monotherapy and combination-based evidence across multiple patient segments.

Regulatory watchers suggest that unless rivals deliver head-to-head superiority or compelling safety trade-offs, TECVAYLI may solidify its place as the backbone bispecific agent of choice in earlier myeloma lines.

Key uncertainties that remain around durability, sequencing, and toxicity mitigation

Despite the strength of the topline results, several unresolved questions may shape how rapidly TECVAYLI can expand in earlier-line settings. Chief among them is the durability of monotherapy responses. While the hazard ratios are compelling, longer-term follow-up will be essential to understand relapse dynamics and resistance patterns post-teclistamab exposure.

Sequencing also remains a challenge. With patients now likely to receive CD38 antibodies like DARZALEX upfront and bispecifics earlier, clinicians will need clearer guidance on how to sequence subsequent therapies. The impact on CAR-T efficacy after prior bispecific exposure remains an area of active investigation, as does the optimal duration of TECVAYLI therapy.

Safety will also continue to be closely watched. Even if CRS and ICANS are manageable, real-world adoption depends on consistent implementation of mitigation protocols. The need for REMS program compliance and specialized monitoring may limit initial uptake in smaller or rural practices.

What to expect from Johnson & Johnson in terms of regulatory filings and market signals

Based on the statistical strength and clinical relevance of MajesTEC-9, industry observers expect Johnson & Johnson to pursue label expansion with the U.S. Food and Drug Administration and European regulators in the near term. This would potentially position TECVAYLI for earlier-line use as monotherapy in relapsed/refractory multiple myeloma by late 2026 or early 2027, depending on review timelines and confirmatory data submissions.

Analysts will also be watching closely for presentation of the full MajesTEC-9 data at an upcoming hematology conference, most likely EHA or ASCO. This will provide additional granularity on response durability, subgroup analyses, and safety trends that could influence clinical adoption.

With nearly 21,000 patients treated globally and growing recognition of bispecifics as a scalable alternative to autologous cell therapy, TECVAYLI appears poised to reshape the immunotherapy landscape in multiple myeloma—especially if it secures earlier-line approval.

  bispecific antibody, DARZALEX FASPRO, immunotherapy, Johnson & Johnson, MajesTEC-9, multiple myeloma, oncology trials, relapsed/refractory, teclistamab-cqyv, TECVAYLI